Article Details

Immunotherapy and Targeted Therapies in NSCLC: Phase 3 Data From ESMO 2022

Retrieved on: 2022-09-24 08:43:46

Tags for this article:

Click the tags to see associated articles and topics

Immunotherapy and Targeted Therapies in NSCLC: Phase 3 Data From ESMO 2022. View article details on hiswai:

Excerpt

Long-term survival data from the phase 3 EMPOWER-Lung 1 trial showed that cemiplimab can improve progression-free survival (PFS) and overall ...

Article found on: www.cancertherapyadvisor.com

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up